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Children’s Hospital of Pittsburgh and from peripheral blood (Yao et al., 1995; Fossiez et al.,
1996). However, data in mice (Happel et al., 2003; Ferrettithe University of Pittsburgh
Pittsburgh, Philadelphia et al., 2003) and humans (Shin et al., 1999) have subse-
quently demonstrated that CD8 memory T lympho-2 Department of Allergology & Respiratory Medicine
Institute of Internal Medicine cytes can also produce IL-17A after stimulation, more
specifically the CD45RO subset. Interestingly, IL-17FThe Sahlgrenska Academy at the University of Go¨teborg
S-413 45 Go¨teborg resides just 46,050 base pairs away from IL-17A on chro-
mosome 6 in humans and on chromosome 1 in miceSweden
and, given their similar expression profile in activated T
lymphocytes, suggest that regulatory regions exist
within the IL-17A/F locus, controlling their expression.
IL-17A was cloned more than 10 years ago and six IL- IL-17A expression does not segregate to CD4 T-lym-
17 family members (IL-17A-F) have subsequently been phocytes with a Th1 or Th2 profile (Infante-Duarte et al.,
described. IL-17A is largely produced by activated 2000). In response to stimulation by lipopetides from
memory T lymphocytes but stimulates innate immunity Borrelia burgdorferi, IL-17A localizes to a subset of T
and host defense. IL-17A and IL-17F both mobilize lymphocytes expressing tumor necrosis factor (TNF)-
neutrophils partly through granulopoeisis and CXC and granulocyte-macrophage colony-stimulating factor
chemokine induction, as well as increased survival (GM-CSF) (Infante-Duarte et al., 2000). In support of
locally. IL-17A and IL-17F production by T lymphocytes subsets of T lymphocytes being a major source for IL-
is regulated by IL-23 independent of T cell receptor 17A in host defense, mice which lack T lymphocytes
activation. Increasing evidence shows that IL-17 fam- (SCID) or mice depleted of CD4 and CD8 T lympho-
ily members play an active role in inflammatory dis- cytes (using antibodies) have over a 90% reduction in
eases, autoimmune diseases, and cancer. This places IL-17A concentration within the lung after endotoxin ex-
IL-17 family members and their receptors as potential posure (Ferretti et al., 2003) (Happel et al., 2003). In
targets for future pharmacotherapy. addition to T lymphocytes, IL-17A message or intracellu-
lar protein has been detected in eosinophils and neutro-
IL-17A and the IL-17 Family phils and human blood monocytes but release of free,
Interleukin (IL)-17A was originally described and cloned soluble IL-17A protein has not been reported (Molet et
by Rouvier et al. (1993) and named CTLA8, was subse- al., 2001; Ferretti et al., 2003). (Awane et al., 1999).
quently renamed IL-17, and more recently, IL-17A. The IL-17B was cloned by using a homology-based EST
gene location for IL-17A is 6p12 (Moseley et al., 2003) database search followed by amplification from a fetal
(Table 1), and IL-17A shows 58% homology with an open tissue cDNA library and is expressed as a noncovalent
reading frame of the T lymphotropic herpesvirus samirii dimer (Li et al., 2000; Shi et al., 2000). It is expressed in
(viral IL-17). IL-17A is the prototypic IL-17 family member the pancreas, small intestine, stomach, and in the spinal
(Table 1) in that it is a disulfide-linked homodimeric gly- cord as well (Li et al., 2000; Moore et al., 2002). IL-17C,
coprotein consisting of 155 amino acids (Yao et al., on the other hand, has a different expression profile,
1995), exerting its actions as a homodimer with a molec- being detected in human testes, thymus, spleen, and
ular weight around 35 kDa. Mouse and rat IL-17A dis- prostate (Moseley et al., 2003). IL-17D was cloned by
plays significant structural homology with human IL-17A homology and RACE-PCR and is expressed in skeletal
(Table 1), both having remarkably conserved glycosyla- muscle, neuronal cells, the prostate, and lesser amounts
tion sites (Moseley et al., 2003). Homology-based clon- in resting CD4 T lymphocytes (Starnes et al., 2002). In
ing has recently revealed five additional IL-17 family contrast to IL-17A and IL-17F, IL-17D is not induced in
members (Table 1), termed IL-17B to IL-17F (Li et al., activated B- or T lymphocytes (Starnes et al., 2002). The
2000; Starnes et al., 2001; Hurst et al., 2002; Lee et most divergent known member of the IL-17 family is IL-
al., 2001; Fort et al., 2001). These molecules also form 17E (IL-25) (Figure 1, Table 1); it is expressed in the
homodimers and show conservation in their c-terminal brain, lung, testis, and prostate at low levels in human
region, with five spatially conserved cysteine residues tissues (Lee et al., 2001) and in mouse T lymphocytes
accounting for a characteristic cysteine-knot formation of the CD4 subset with a Th2 profile (Fort et al., 2001).
for IL-17A and IL-17F (Hymowitz et al., 2001). Among
the IL-17 family members, the IL-17F isoforms 1 and 2
Proximal Regulators of IL-17 Family Members(ML-1) have the highest degree of homology with IL-17A
In Vitro and In Vivo(55 and 40% respectively), followed by IL-17B (29%), IL-
IL-17A and IL-17F may now be regarded as molecules17D (25%), IL-17C (23%), and IL-17E (also named IL-
mediating the stimulation of neutrophil mobilization by25) being most distant (17%) (Figure 1).
T lymphocytes (see the section titled “IL-17 Signaling
and Tissue Inflammation” below for further details). This
unique position, at the interface between adaptive and*Correspondence: jay.kolls@chp.edu
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23 in vivo. In contrast, IL-12 p70 signaling via IL-12R2Table 1. Overview of the Human IL-17 Family of Cytokines
decreases IL-17A release from mouse splenocytes
IL-17 Size Length Chromosomal Homology of in vitro (Aggarwal et al., 2003). This differential regulation
Subtype (kDA) (Number of aa) Location Murine to Human
of IL-17 by IL-23 and IL-12 has recently been shown to
A 35 155 6p12 62 occur in vivo as well in the setting of autoimmune arthri-
B 41 180 5q32-34 88 tis, as IL-12 p35-deficient mice have a higher frequency
C 40 197 16q24 83 of IL-17A-producing T cells and exacerbated inflamma-
D 52 202 13q12.11 78
tion (Murphy et al., 2003). Thus, several members of theE 34 161 14q11.2 81
IL-12 family of cytokines, including IL-27, may regulateF 44 153 6p12 77
IL-17 responses. Since IL-12 largely signals through
All cytokines in this table are homodimeric glycoproteins incorporat-
STAT4 and IL-23 induces STAT3/4 heterodimers (Trin-ing cysteine residues and disulphide linkages (except IL-17B).
chieri et al., 2003), the regulation of IL-17 family mem-
bers by IL-12 family members deserves further charac-
terization (Figure 2).
innate immunity, has potential implications not only for
host defense but also for specific inflammatory dis-
eases. Recently, major research efforts have focused Receptors for IL-17 Family Members
The originally described IL-17 receptor (IL-17R) (Yao eton defining upstream regulators of IL-17 family mem-
bers. Two cytokines, IL-15 and IL-23, have been shown al., 1995) (Table 2) is a type I transmembrane protein
consisting of a 293 amino acid extracellular domain, ato regulate the release of the T lymphocyte-expressed
IL-17 family members. IL-15 induces IL-17A production 21 amino acid transmembrane domain, and a long 525
amino acid cytoplasmic tail (Yao et al., 1995). Its mRNAin CD4, but not CD8, T lymphocytes from mice (Fer-
retti et al., 2003). This action of IL-15 has also been is extensively expressed in the lungs, kidneys, liver, and
spleen as well as in isolated fibroblasts, epithelial cells,confirmed in human blood mononuclear cells cultured
in vitro (Ziolkowska et al., 2000). The role of IL-15 in mesothelial cells, and various myeloid cells from rats
and mice (Yao et al., 1995). Among human cells, theregulating IL-17A and IL-17F in vivo has yet to be deter-
mined but, as IL-15 is critical for the maintenance of T messenger RNA for IL-17R can be detected in epithelial
cells, fibroblasts, B and T lymphocytes, myelomonocyticlymphocytes of the memory subset, the IL-15–IL-17 axis
may be critical in chronic inflammation. cells, and marrow stromal cells (Silva et al., 2003). The
IL-17R protein itself can be detected in peripheral bloodCompared with the case for IL-15, an even stronger
case can be made for IL-23 as a proximal regulator of T lymphocytes and in vascular endothelial cells from
humans (Moseley et al., 2003). Remarkably, the humanIL-17A and IL-17F. IL-23 is a heterodimer, consisting of
the unique IL-23 p19 subunit and the p40 subunit it IL-17R binds IL-17A with a relatively low affinity and at
a potency that is approximately 10-fold weaker than theshares with IL-12 (Oppmann et al., 2000). This proximal
regulator signals through the IL-121 and IL-23 receptor, cytokine response (IL-6 release) to IL-17A, arguing that
there may be additional receptors involved in IL-17A-and it potently induces IL-17A and IL-17F in human
and mouse T lymphocytes. IL-23 specifically stimulates induced cell signaling (Yao et al., 1995). However, evi-
dence does not support an additional high-affinity sub-memory (CD44high/CD62Llow) CD4 T-lymphocytes to
produce IL-17A, although mouse CD8 T-lymphocytes unit receptor, as mice with a homozygous deletion of
IL-17R have no detectable binding of IL-17A in B- or Talso respond to IL-23 in vitro (Aggarwal et al., 2003;
Happel et al., 2003). Importantly, T lymphocytes stimu- lymphocytes (Ye et al., 2001b). Moreover, homozygous
deletion of IL-17R abrogates the increase in splenic neu-lated with either endotoxin or heat-killed, gram-negative
bacteria do not produce IL-17A, unless dendritic cells trophil progenitors resulting from the overexpression of
IL-17A (Ye et al., 2001b). Because IL-17F has a highare present (Happel et al., 2003). The IL-17A response
by T lymphocytes is dependent upon dendritic cells degree of homology with IL-17A and has a similar spec-
trum of activity in terms of induction of G-CSF andproducing IL-23 through a Toll-like receptor 4-depen-
dent pathway (Happel et al., 2003). Thus, IL-23 induces CXCL8 (Hurst et al., 2002), IL-17F may use IL-17R for
signaling; however, neither binding nor competition ex-the production of IL-17A in T lymphocytes, without re-
quiring classical physical cell-to-cell contact between periments have supported this (Hymowitz et al., 2001).
Five additional IL-17 receptors have now been de-these cells and dendritic cells in vitro (Happel et al.,
2003). Inhibiting IL-15 does not affect this IL-17A pro- scribed; these are IL-17RB-E (Table 2). Similar to IL-17
R, they are type I transmembrane proteins but displayduction and, thus, IL-15 is not required for the induction
of IL-17A by gram-negative bacteria. Taken together, it significant alternative splicing (Moseley et al., 2003). IL-
17RB (aka Evi27) is expressed in human kidney, pan-is likely that both IL-17A and IL-17F are regulated by IL-
Figure 1. Dendogram Analysis of IL-17 Fam-
ily Members
Protein sequences of IL-17 family members
were aligned and phylogenetically character-




Figure 2. Hypothesized IL-17 Signaling in Airway Inflammation
Mucosal T-lymphocytes can produce IL-17A/F in response to proximal triggers such as IL-23 from macrophages or dendritic cells or IL-15,
and IL-17A/F can signal via receptors expressed on epithelial cells, fibroblast, and endothelial cells. IL-17A/F subsequently induces chemokines
(CXCL8, CXCL6, CXCL1), growth factors (G-CSF, GM-CSF, IL-6), and adhesion molecules (ICAM-1), leading to augmented neutrophil accumula-
tion as well as to granulopoeisis. IL-12p70 can inhibit IL-17 A/F elaboration by T cells.
creas, liver, brain, and intestines and serves as a recep- prostate, and pancreas, but its ligand preferences re-
main to be described in detail (Clark et al., 2003).tor for IL-17B as well as for IL-17E with IL-17E binding
more avidly than IL-17B (Shi et al., 2000; Lee et al., 2001).
IL-17RC is expressed in human prostate, cartilage, kid- IL-17 Signaling and Tissue Inflammation
Most experimental evidence to date suggests a roleney, liver, heart, and muscle (Haudenschild et al., 2002;
Moseley et al., 2003). Interestingly, this receptor under- for IL-17 family members in coordinating local tissue
inflammation mainly via the induced release of proin-goes alternative splicing with some forms being se-
creted but potentially maintaining ligand binding capa- flammatory and neutrophil-mobilizing cytokines (Fig-
ure 2).bilities, and thus these isoforms may potentially inhibit
IL-17 receptor family members from ligand-induced sig- Studies in Vitro
C-X-C Chemokines. Stimulation with recombinant IL-17Analing (Haudenschild et al., 2002). IL-17RD also exhibits
alternative splicing as well (Moseley et al., 2003), and (rIL-17A) protein causes the production and release of
CXCL8 (IL-8) in human bronchial epithelial and venousone such product may inhibit fibroblast growth factor
(FGF)-induced receptor tyrosine kinase activity (Yang et endothelial cells, as well as in human synoviocytes ob-
tained from rheumatoid synovium (Laan et al., 1999;al., 2003). Finally, IL-17RE is expressed in human brain,
Table 2. Overview of the Human IL-17 Receptor Family
IL-17 R Ligand Length Chromosomal Homology of
Subtype Specificity (Number of aa) Location Murine to Human (%)
IL-17R IL-17A/?IL-17F 866 22q11.1 68
IL-17RB (IL-17RH1) IL-17B/IL-17E 499* 3p21.1 82
IL-17RC (IL-17RL) unknown 791* 3p25.3 71
IL-17RD(hSEF) ?ligand for FGF-R 595* 3p21.2 90
IL-17RE unknown 667* 3p25.3 82
* Alternatively spliced isoforms exist.
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Fossiez et al., 1996; Laan et al., 2001; Kawaguchi et al., IL-6 and Mucins. Tissue fibroblasts and human bron-
chial epithelial cells respond to IL-17A by releasing the2001a; Prause et al., 2003; Jones and Chan, 2002). This
is of interest since these cell types represent critical potentially neutrophil-activating cytokine IL-6 in vitro,
and this activity has been used as a bioassay for IL-17Abarriers for neutrophil invasion. CXCL8 accounts for a
significant component of IL-17A- induced chemotactic (Yao et al., 1995) (Kawaguchi et al., 2001a; Molet et al.,
2001). Similar to CXCL8, the involvement of the MAPactivity, as a neutralizing anti-CXCL8 antibody signif-
icantly attenuates the human neutrophil chemotactic kinase ERK has been confirmed (Laan et al., 1999; Kawa-
guchi et al., 2001a). However, it is not known whetheractivity of conditioned media obtained from IL-17A stim-
ulated bronchial epithelial cells (Laan et al., 1999). More- this response is sensitive to glucocortocoids. Among all
the interleukins from IL-1 to IL-18, only IL-6 and IL-17Aover, CXCL8 release is specific for IL-17A protein as well,
as pretreatment of rIL-17A with a specific neutralizing can increase mRNA and protein for the mucins MUC5AC
and MUC5B, at least in primary human bronchial epithe-antibody attenuates its effect. Similarly, IL-17F stimu-
lates CXCL8 in fibroblasts (Hymowitz et al., 2001), and lial cells in vitro (Chen et al., 2003). For IL-17A, this
effect, in part, is mediated by IL-17-induced IL-6, whichIL-17D can induce CXCL8 in endothelial cells, possibly
through nuclear translocation of NF-B (Starnes et al., subsequently results in an increase in mucin protein in
these cells. Interestingly, IL-17B, IL-17C, and IL-17F also2002). IL-17E also activates nuclear factor-kappa B (NF-
B) through IL-17BR and results in CXCL8 induction in induce IL-6 in human fibroblasts, whereas IL-17D in-
duces IL-6 in human venous endothelial cells in vitro (Likidney cells (Lee et al., 2001). Stimulation with IL-17A
or IL-17F also releases CXCL1 (growth related oncogene et al., 2000; Starnes et al., 2002; Awane et al., 1999).
MCP-1. Stimulation with IL-17A also induces an in-(GRO)-) and granulocyte chemotactic protein (GCP)-2
in human bronchial epithelial and mesothelial in vitro crease in the messenger RNA for the C-C chemokine
monocyte chemotactic protein (MCP)-1 in rat intestinal(Prause et al., 2003; Jones and Chan, 2002; Witowski et
al., 2000). The induced gene expression and protein epithelial cells in vitro (Awane et al., 1999). Even though
this finding may have interesting implications for therelease for CXCL8 and CXCL1 induced by IL-17A is
comparable with that caused by the proinflammatory accumulation of monocyte-lineage cells in the tissue
of several organs, its functional importance remains tocytokine TNF- (Jones and Chan, 2002). It is not yet
confirmed whether stimulation with IL-17A or IL-17F in- be characterized.
TNF- and IL-1. Certain monocytic cells respondduces the release of CXCL8 and other C-X-C chemo-
kines via a NF-B-inducing kinase in resident lung cells, to IL-17A by releasing proinflammatory cytokines when
cultured in vitro. For example, isolated human bloodas is the case for CXCL8 in response to proinflammatory
stimuli other than IL-17A (Mori et al., 1999; Harper et monocytes release TNF- and IL-1 when stimulated
with rIL-17A in vitro (Jovanovic et al., 1998). Noteworthy,al., 2001; Kennedy et al., 1998). However, in human sy-
noviocytes in vitro IL-17A induction of CXCL8 depends however, alveolar and peritoneal macrophages from
mice lack IL-17R expression and fail to secrete TNF-,upon NF-B and the PI-3 kinase/Akt pathway (Hwang
et al., 2004). as well as CXCL2 and IL-6 in response to IL-17A (Kolls
et al., 2003). Moreover, studies in the human monocyticMitogen-activated protein (MAP) kinases, in particular
p38 and extracellular signal-regulated kinase (ERK), are cell line, THP-1, IL-17B and IL-17C, but not IL-17A, in-
duce TNF- and IL-1 (Li et al., 2000). It therefore re-involved as mediators of IL-17A-induced release of C-X-C
chemokines in human bronchial epithelial cells in vitro mains unknown what human macrophage populations
can directly respond to the various IL-17 family mem-(Laan et al., 2001; Kawaguchi et al., 2001a; Prause et
al., 2003). In IL-17A-induced bronchial epithelial cells, bers; however, data strongly support a role for IL-17B
and C in monocyte TNF- and IL-1 production.the release of CXCL8, CXCL1, and CXCL6 release, and
the CXCL8 release in primary human bronchial smooth Colony-Stimulating Factors. IL-17A and IL-17D can in-
duce the production and/or release of at least two differentmuscle cells is relatively insensitive to glucocortocoid
inhibition (Vanaudenaerde et al., 2003; Prause et al., colony-stimulating factors in vitro. This includes granulo-
cyte colony-stimulating factor (G-CSF) in venous endo-2003; Jones and Chan, 2002). In contrast, primary hu-
man lung fibroblasts, optimally located to communicate thelial cells and fibroblasts as well as GM-CSF in bron-
chial epithelial cells from humans (Jones and Chan,with the neutrophil after extravasation into lung tissue,
produce CXCL8 in response to IL-17A, and these re- 2002; Starnes et al., 2002). The effect of IL-17A on GM-
CSF is regulated by glucocortocoids and is probably asponses are sensitive to glucocorticoid inhibition in vitro
(Molet et al., 2001). Taken together, these data suggest functionally significant one, as judged from its impact
on survival of isolated human blood neutrophils culturedthat IL-17A signaling differs among resident lung cells.
Similar to the case in human bronchial epithelial cells, in vitro (Laan et al., 2003). IL-17A increases G-CSF by
both increasing its transcription and by stabilizing itsIL-17A induces an increase in the mRNA for another
C-X-C chemokine, CINC, in rat intestinal epithelial cells mRNA in mouse fibroblasts in vitro (Cai et al., 1998),
and this effect on G-CSF production appears to be inde-in vitro (Awane et al., 1999). The activation of the CINC
mRNA promoter involves TNF receptor-associated fac- pendent of the activation of tyrosine kinase. The in-
crease in G-CSF by IL-17A is associated with an increasetor-6 (TRAF6) (Awane et al., 1999). This mRNA expres-
sion is also dependent upon a NF-B-inducing kinase in neutrophil progenitors in vitro (Fossiez et al., 1996).
In contrast, IL-17D, which induces GM-CSF and IL-6, but(NIK), as well as IB kinase (IKK)-. Furthermore, the
expression of CINC mRNA involves MAP kinases, in- not G-CSF, in human venous endothelial cells actually
suppresses the colony formation of neutrophil progeni-cluding ERK and p38, as well as the Ras pathway. Lastly,
IL-17A was also shown to inhibit cellular proliferation of tors in vitro (Starnes et al., 2002). Furthermore, unlike
IL-17A, IL-17F does not support proliferation of granulo-rat intestinal epithelial cells as well (Awane et al., 1999).
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cyte precursors in vitro (Starnes et al., 2001) despite a of IL-4 and IL-13, and subsequent IL-4/IL-13 signaling
as overexpressing IL-17E in IL-4R knockout mice weresimilar potency to IL-17A in the recruitment of neutro-
phils into the lungs of mice in vivo (Hurst et al., 2002). protected from this gastrointestinal and lung pathology.
In line with its accumulating effect on neutrophils,Functional Interactions with Other Cytokines. The fact
that responses to IL-17A can functionally interact with local stimulation with IL-17A enhances the concentra-
tion of CXCL2 in the bronchoalveolar space of rats andresponses to other cytokines is very likely to have bear-
ing for several inflammatory diseases. For example, co- mice in vivo (Laan et al., 1999; Ye et al., 2001a). In addi-
tion, IL-17A-induced release of CXCL1 also plays a rolestimulation of human airway epithelial cells with TNF-
enhances the release of CXCL8 and CXCL1, compared for neutrophil accumulation in the bronchoalveolar space
of mice in vivo (Ferretti et al., 2003; Kolls et al., 2003).with the effect of IL-17A alone (Laan et al., 1999; Jones
and Chan, 2002). There is also evidence of IL-17A syner- This is true for the potentially neutrophil-activating cyto-
kine IL-6 as well (Hoshino et al., 1999). GM-CSF alsogizing with TNF- in causing de novo synthesis CXCL1
in human mesothelial cells in vitro, which may be due appears to be involved in neutrophil accumulation
caused by IL-17A in vivo, at least after costimulationto an increased stability of CXCL1 mRNA (Witowski et
al., 2000). Furthermore, in rat intestinal epithelial cells with TNF- (Laan et al., 2003). IL-17A may also regulate
neurogenic inflammation as endogenous tachykininsin vitro, IL-17A and IL-1 synergize in activating the
promoter of the C-X-C chemokine CINC (Awane et al., enhance the IL-17A-induced neutrophil accumulation
in the bronchoalveolar space of rats in vivo via NK-11999). In addition, costimulation with IL-17A and the Th1
cytokine IFN- enhances the CXCL8 response com- receptors (Hoshino et al., 1999). Interestingly, overexpres-
sion of IL-17A systemically results in massive extramedul-pared with IL-17A alone in human bronchial epithelial
cells in vitro as well (Kawaguchi et al., 2001a). Interest- lary hematopoiesis in mice in vivo, caused by the induction
of endogenous G-CSF and stem cell factor (SCF) (Schwarz-ingly, certain cytokines typically implicated in Th2-like
conditions (i.e., IL-4 and IL-13) enhance the CXCL8 re- enberger et al., 1998, 2000). Overexpression of IL-17A
in the joint space of mice results in exacerbation ofsponse to IL-17A in human bronchial epithelial cells
in vitro (Kawaguchi et al., 2001a). Similar to the case for collagen-induced arthritis independent of IL-1, and is
associated with augmented neutrophil recruitment asCXCL8, the release of the colony-stimulating factors
G-CSF and GM-CSF, is enhanced by costimulation with well (Lubberts et al., 2001).
Local Neutrophil Activity. IL-17A can also activateTNF- and IL-17A in human bronchial epithelial cells
in vitro (Jones and Chan, 2002; Laan et al., 2003). Of neutrophils under certain conditions in vivo, even though
this activation may be restricted to certain neutrophilpotential importance for neutrophil recruitment into the
bronchoalveolar space, costimulation with IL-17A and proteases. Local administration of rIL-17A into the bron-
choalveolar space causes a local increase in neutrophilIFN- markedly enhances intercellular adhesion mole-
cule (ICAM)-1 protein in human bronchial epithelial cells, elastase (NE) and myeloperoxidase (MPO) activity in rats
in vivo (Hoshino et al., 2000). Despite these in vivo data,even though IL-17A has no effect of ICAM-1 expression
when used as costimulation with IL-4 or IL-13 (Kawa- no corresponding effect on MPO is observed in isolated
blood neutrophils from rats after stimulation with rIL-guchi et al., 2001a). Given the fact that IL-17B and IL-
17C are potent inducers of TNF- and IL-1 (Li et al., 17A in vitro. The activating effect observed with IL-17A
in vivo may therefore be mediated through indirect2000), it can be speculated that there are synergistic
proinflammatory activities in between the different IL- mechanisms, similar to what is the case for IL-17A’s
accumulating effect on neutrophils in organs in vivo. For17 family members.
Studies In Vivo comparison, given in a dose of that is equally potent to
IL-17A in terms of neutrophil accumulation, rIL-1 doesImmune Cell Recruitment. IL-17A lacks a direct effect
on chemotaxis for human blood neutrophils in vitro, not increase NE or MPO activity after local administra-
tion in the bronchoalveolar space of rats in vivo (Hoshinowhereas it causes a substantial accumulation of neutro-
phils in a compartmentalized fashion in the bronchoal- et al., 2000). However, local costimulation with rIL-1
plus IL-17A, resulting in a similar magnitude of neutrophilveolar and joint space of rats and mice in vivo (Ye et
al., 2001a; Laan et al., 1999; Miyamoto et al., 2003; Hos- accumulation, results in substantially more NE and MPO
activity compared with IL-17A alone (Hoshino et al.,hino et al., 1999, 2000). This in vivo response to rIL-17A
in the bronchoalveolar space in vivo is blocked by a 2000). This likely represents true synergism for IL-17A
and IL-1. However, the activating effect on neutrophilsneutralizing and specific anti-IL-17 antibody (Laan et al.,
1999) in addition to pretreatment with glucocortocoids is not associated with a commensurate increase in ma-
trix metalloproteinase (MMP)-9 as rIL-17A increases lo-(Laan et al., 1999). Expression of IL-17C, IL-17E, and IL-
17F also result in significant neutrophil recruitment into cal MMP-9 no more than the number of neutrophils in
the bronchoalveolar space of mice in vivo (Prause et al.,the lung, whereas IL-17E also resulted in significant emi-
gration of eosinophils (Hurst et al., 2002) consistent with 2004). Taken together, even though the exact mecha-
nisms may differ for each proteolytic enzyme, these dataits Th2 cytokine profile. Furthermore, forced expression
of IL-17E (IL-25) results in increased eosinophilia, IgE, indicate that IL-17A and likely, other IL-17 family mem-
bers, are involved in determining the net proteolytic loadIL-4, IL-5, and lL-13 production, resulting in multiorgan
inflammation (Pan et al., 2001; Kim et al., 2002). Similar locally in inflamed tissue (Prause et al., 2004).
Models of Joint Disease. The role of IL-17 family mem-findings have been reported by Fort and colleagues
where overexpression of IL-17E resulted in hypertrophy bers in arthritis has recently been extensively reviewed
(Lubberts, 2003). In line with IL-17A determining localof the duodenum, mucous accumulation, and eosino-
philic inflammation of the gastrointestinal tract and lung proteolytic load, abrogation of IL-17A attenuates anti-
gen-induced arthritis in mice in vivo (Bush et al., 2002;(Fort et al., 2001). These findings were due to induction
Immunity
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Lubberts et al., 2004). Also, treatment with anti-IL-17A exposure to allergen. However, it remains unclear
whether blocking endogenous IL-17A alters the genera-antibodies after the onset of experimental, collagen-
induced arthritis decreases radiologic joint damage and tion of antigen-specific CD4 T-lymphocytes in mice
in vivo (Hellings et al., 2003). Indeed, one study in IL-histologic destruction of cartilage and bone as well as
reduces IL-6 in serum of mice in vivo (Lubberts et al., 17A knockout mice does suggest that IL-17A is critical
for proliferation of CD4 T-lymphocytes with a Th2 pro-2004). Thus, as judged from these studies, IL-17A and
IL-17F may contribute to erosion of cartilage and bone file, as well as for IL-4 and IL-5 production, and for
specific bronchial hyper-responsiveness to allergenin joint disease. In line with this idea, the loss of the
proximal regulator IL-23 is protective in autoimmune (Nakae et al., 2002).
IL-17E, with its unique immunological profile, causesarthritis in mice, whereas in contrast, the loss of IL-12 is
associated with exacerbated arthritis and an increased eosinophil accumulation in the bronchoalveolar space
and nonspecific bronchial hyperreactivity, accompaniednumber of IL-17A-secreting T lymphocytes as well (Mur-
phy et al., 2003). by a local increase in mRNA for IL-5, IL-13, IFN-, CXCL5
(LIX), and CCL11 (Eotaxin) in mice in vivo (Hurst et al.,Models of Host Defense. Substantial evidence from
mice in vivo support a critical role of endogenous IL- 2002; Fort et al., 2001). These observations clearly illus-
trate the fundamental functional differences among dif-17s in neutrophil recruitment and host defense. IL-17A,
and IL-17F, is induced in a dose- and time-dependent ferent members within the IL-17 cytokine family. The
precise role of endogenous IL-17B, IL-17C, IL-17D, andfashion in response to gram-negative bacteria such as
Klebsiella pneumoniae (Ye et al., 2001a, 2001b). Similar IL-17F needs to be further defined.
Models of Malignancy. Both human cervical cancerresults have been observed with endotoxin as well (Lars-
son et al., 2000). Mice lacking IL-17R succumb to bacte- and murine fibrosarcoma cell lines from that are trans-
fected with the IL-17A cDNA show significantly greaterremia and early death after pulmonary challenge to Kleb-
siella pneumoniae (Ye et al., 2001b). This is likely due tumor formation in vivo in nude mice and C57BL/6 mice,
respectively (Tartour et al., 1999; Numasaki et al., 2003).to remarkably diminished recruitment of neutrophils into
the bronchoalveolar space related to a reduced splenic In line with this, induced expression of IL-17A enhances
angiogenesis within a model of fibrosarcoma tumors ingranulopoeitic response to the infection and attenuation
of local G-CSF production (Ye et al., 2001b). In confirma- mice (Numasaki et al., 2003). Whereas IL-17A stimulates
endothelial cord formation and the secretion of VEGF,tion of data in the IL-17R knockout mouse, antibody
neutralization of IL-17A significantly attenuates neutro- PGE1, and PGE2 in murine lung fibroblasts from in vitro
(Numasaki et al., 2003, 2004), it has no effect on cellularphil accumulation after local administration of endotoxin
administration in the lung (Miyamoto et al., 2003; Ferretti proliferation on human cervical carcinoma cells in vitro
(Tartour et al., 1999). However, overexpression of IL-17Aet al., 2003).
Furthermore, endogenous IL-17A, released mainly by increases macrophage recruitment in cervical cancer
(Tartour et al., 1999). Finally, IL-17A increases cytotoxicCD4 T-lymphocytes, also plays a critical role in orches-
trating the formation of intra-abdominal abscesses and T lymphocyte generation in an immunocompetent my-
eloid malignancy model in mice (Benchetrit et al., 2002).neutrophil accumulation in response to the gram-nega-
tive bacteria Bacteroides fragilis in vivo (Chung et al., Interestingly, IL-17F, being similar to IL-17A, inhibits
vessel tube formation in human umbilical venous endo-2003). The in vivo mechanisms involved in the abscess
formation include costimulation of T lymphocytes via thelial cells (Starnes et al., 2001). IL-17 family members
may thus exert both pro- or antitumor effects, dependingthe CD28-B7 pathway, and the abscess formation is
paralleled by a local increase in IL-17A protein, de- on the immunogenicity of the tumor, the immune status
of the host, and the angiogenic activity of the IL-17pending upon STAT 4 signaling (Chung et al., 2003).
Systemic pretreatment with a specific and neutralizing family member.
Studies in Humans. There are now several clues toanti-IL-17A antibody attenuates abscess formation.
Taken together, IL-17A and IL-17F constitute crucial fac- the potential role of the IL-17 family of cytokines in
human lung disease. Healthy human volunteers with in-tors produced by T lymphocytes in orchestrating the
neutrophil component of innate immunity during host duced, severe airway inflammation due to the exposure
to a swine confinement, display a pronounced increasedefense. In addition, the expression pattern of IL-17RB
in the gastrointestinal tract is compatible with a role for in the concentration of free, soluble IL-17A protein in
the bronchoalveolar space (Laan et al., 2002). This isIL-17B and IL-17E in host defense/inflammation of the
gut as well (Shi et al., 2000; Lee et al., 2001). associated with a local accumulation of neutrophils and
lymphocytes as well. However, it is not known how theseModels of Allergy and Adaptive Immunity. IL-17A also
regulates neutrophil recruitment in response to allergen events relate to the increased long-term morbidity in
lung disease among swine farmers (Reynolds et al.,in the bronchoalveolar space as well. In ovalbumin-sen-
sitized mice, airway allergen challenge is followed by 1996). In further support of IL-17A being involved in lung
disease, patients with mild asthma display a detectablede novo synthesis of IL-17A in the lungs (Hellings et
al., 2003). Moreover, abrogation of endogenous IL-17A increase in the local concentration of free, soluble IL-
17A protein (Molet et al., 2001). Moreover, there is ansignificantly attenuates allergen-induced neutrophil ac-
cumulation in the bronchoalveolar space of mice in vivo association between asthma and an increase in immu-
noreactivity for intracellular IL-17A protein in inflamma-(Hellings et al., 2003). Interestingly, the referred abroga-
tion of IL-17A increases IL-5 and eosinophil accumula- tory cells from the bronchoalveolar space. Compatible
with this, a study on nasal polyps has shown an in-tion in the same compartment as well. These data sug-
gest that IL-17A is involved in determining the balance creased subepithelial expression of IL-17A among
atopic patients (Molet et al., 2003). A study analyzingbetween neutrophil and eosinophil accumulation after
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induced sputum from patients with either asthma or granulocytes. To date, most published evidence sup-
ports a role for IL-17A, and possibly IL-17F, as a pro-chronic obstructive pulmonary disease (COPD) claims
that there is no substantial difference in the concentra- moter of granulopoeisis, neutrophil accumulation, and
neutrophil activation in the lung, joint space, centraltion of free, soluble IL-17A for asthma compared with
healthy airways, although IL-17A levels were higher in nervous system, and intestinal tissue. The production
of IL-17A and IL-17F by T lymphocytes is regulated prox-asthma than in COPD (Barczyk et al., 2003). In spite of
a small study population, a positive correlation between imally by IL-23 produced by dendritic cells, indepen-
dently of cell-to-cell contact or traditional TCR activationlocal IL-17A and nonspecific bronchial responsiveness
was shown when the sample size was pooled for analy- (Figure 2). This places IL-17A, and most likely IL-17F
as well, as an important player in host defense andsis. In addition to this, a recent study demonstrated that
allergen challenge can increase local IL-17F (ML-1) in autoimmunity. Thus, IL-17A and IL-17F may be uniquely
positioned at the interface of adapted and innate immu-patients with allergic asthma (Kawaguchi et al., 2001b).
Interestingly, the “Th2-biased” IL-17 family member, IL- nity. Moreover, IL-17B and IL-17C may exert a coopera-
tive proinflammatory action together with IL-17A and IL-17E, displays a local increase in acute sinusitis (Casado
et al., 2004). Despite these observations, there are no 17F by regulating TNF- and IL-1 release, which can
potentiate the effects of IL-17A and IL-17F on the localreports of IL-17E in asthma to date.
There are increasing data supporting a role of IL-17 the secretion of C-X-C chemokines and growth factors
in tissue. Furthermore, IL-17E with is Th2 profile pro-family members in autoimmunity. Patients with inflam-
matory bowel disease display an elevated expression vides a strong rationale to further characterizing this IL-
17 family member in allergic disease. In addition, theof IL-17A mRNA and intracellular protein in the intestinal
mucosa (Fujino et al., 2003). Specifically, this is true in extensive and specific distribution patterns of the indi-
vidual receptor subtypes for the IL-17 family membersthe colonic mucosa of patients with either ulcerative
colitis or Crohn’s disease when compared with corre- are compatible with their involvement in a wide range of
inflammatory diseases. Future studies in humans shouldsponding samples from normal subjects or patients with
infectious or ischemic colitis (Fujino et al., 2003). IL-17A further elucidate the potential therapeutic utility of drugs
targeting IL-17 family members and their receptors inexpression is augmented in gut tissue and detectable
in the serum of patients with active exacerbations of inflammatory and neoplastic disease.
inflammatory bowel disease. In arthritis, IL-17A regu-
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